Trial ID or NCT#

NCT00997503

Status

NOT RECRUITING

Purpose

The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen.

This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Study).

Official Title

TAXUS Libertē Post Approval Study: A U.S. Post-Approval Study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

David Lee, MD
Interventional cardiologist, Cardiologist
Associate Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Todd Brinton
Interventional cardiologist, Cardiologist
Clinical Professor, Medicine - Cardiovascular Medicine
Alan Yeung, MD
Interventional cardiologist, Cardiologist
The Li Ka Shing Professor in Cardiology
William Fearon, MD
Interventional cardiologist, Cardiologist
Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Jennifer Tremmel
Interventional cardiologist, Cardiologist
Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Yvonne Strawa
(650) 498-7028